| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.75 [0.66, 0.85] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.75 [0.65, 0.87] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.79 [0.68, 0.90] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.77 [0.68, 0.86] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | important | - |
| objective responses (ORR) | 1.27 [0.85, 1.91] | | > 1 | | 68% | 3 studies (3/-) | 87.7 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 0.84 [0.56, 1.25] | | > 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 3.21 [0.43, 23.85] | | < 1 | | 49% | 2 studies (2/-) | 12.8 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.06 [0.85, 1.33] | | < 1 | | 0% | 3 studies (3/-) | 30.0 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 0.81 [0.42, 1.55] | | < 1 | | 38% | 3 studies (3/-) | 74.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.08 [0.92, 4.69] | | < 1 | | 75% | 3 studies (3/-) | 3.9 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.00 [0.35, 2.90] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.93 [0.66, 1.31] | | < 1 | | 35% | 2 studies (2/-) | 66.1 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 0.77 [0.51, 1.15] | | < 1 | | 0% | 1 study (1/-) | 90.3 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.91 [0.48, 1.72] | | < 1 | | 72% | 2 studies (2/-) | 61.6 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.51 [0.30, 0.86] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 1.22 [0.77, 1.92] | | < 1 | | 8% | 3 studies (3/-) | 20.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.95 [0.76, 1.18] | | < 1 | | 6% | 3 studies (3/-) | 69.1 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.25 [0.55, 2.82] | | < 1 | | 0% | 3 studies (3/-) | 29.5 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.17 [0.54, 2.50] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.75 [0.17, 3.38] | | < 1 | | 0% | 1 study (1/-) | 64.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.85 [0.23, 14.67] | | < 1 | | 0% | 3 studies (3/-) | 28.1 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 1.16 [0.27, 5.04] | | < 1 | | 0% | 3 studies (3/-) | 42.3 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.87 [0.52, 1.45] | | < 1 | | 60% | 3 studies (3/-) | 70.5 % | low | not evaluable | high | non important | - |
| Arthritis TRAE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.63 [0.20, 1.96] | | < 1 | | 0% | 2 studies (2/-) | 78.9 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.11 [0.15, 8.06] | | < 1 | | 7% | 2 studies (2/-) | 46.0 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.72 [0.10, 5.19] | | < 1 | | 0% | 3 studies (3/-) | 62.9 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.76 [0.11, 5.28] | | < 1 | | 23% | 3 studies (3/-) | 60.8 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 3.09 [0.45, 21.45] | | < 1 | | 0% | 3 studies (3/-) | 12.8 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.77 [0.63, 4.94] | | < 1 | | 0% | 3 studies (3/-) | 13.9 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 1.70 [0.52, 5.57] | | < 1 | | 0% | 3 studies (3/-) | 19.1 % | low | not evaluable | high | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.64 [0.35, 1.17] | | < 1 | | 0% | 2 studies (2/-) | 92.7 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.98 [0.07, 59.51] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 6.04 [0.72, 50.41] | | < 1 | | 0% | 2 studies (2/-) | 4.9 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.32 [0.15, 11.31] | | < 1 | | 0% | 3 studies (3/-) | 40.1 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.00 [0.10, 9.62] | | < 1 | | 0% | 3 studies (3/-) | 50.1 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.00 [0.10, 9.62] | | < 1 | | 0% | 3 studies (3/-) | 50.1 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 8.25 [1.02, 66.42] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 4.02 [0.45, 36.30] | | < 1 | | 0% | 1 study (1/-) | 10.9 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 1.20 [0.79, 1.83] | | < 1 | | 0% | 3 studies (3/-) | 19.7 % | low | not evaluable | high | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.00 [0.06, 16.06] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.58 [0.14, 2.37] | | < 1 | | 0% | 3 studies (3/-) | 77.5 % | low | not evaluable | high | non important | - |
| Nephritis TRAE (grade 3-4) | 1.99 [0.18, 22.08] | | < 1 | | 0% | 2 studies (2/-) | 28.8 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.83 [0.61, 1.14] | | < 1 | | 44% | 3 studies (3/-) | 87.1 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.79 [0.11, 5.62] | | < 1 | | 0% | 2 studies (2/-) | 59.4 % | low | not evaluable | high | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.33 [0.03, 3.17] | | < 1 | | 0% | 1 study (1/-) | 83.1 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 89.04] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 6.02 [0.30, 120.88] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.55 [0.35, 6.80] | | < 1 | | 0% | 3 studies (3/-) | 28.2 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 3.80 [0.36, 40.13] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | low | not evaluable | high | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 3.81 [0.36, 40.15] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.98 [0.58, 1.63] | | < 1 | | 47% | 3 studies (3/-) | 53.7 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 2.00 [0.07, 60.06] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.57 [0.18, 1.86] | | < 1 | | 0% | 3 studies (3/-) | 82.2 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 1.19 [0.24, 5.81] | | < 1 | | 0% | 2 studies (2/-) | 41.7 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.69 [0.30, 1.54] | | < 1 | | 80% | 2 studies (2/-) | 81.9 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.92 [0.42, 2.01] | | < 1 | | 0% | 2 studies (2/-) | 58.1 % | low | not evaluable | high | non important | - |
| Back pain AE (grade 3-4) | 2.01 [0.28, 14.34] | | < 1 | | 0% | 2 studies (2/-) | 24.4 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 1.12 [0.15, 8.23] | | < 1 | | 8% | 2 studies (2/-) | 45.7 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 1.12 [0.15, 8.23] | | < 1 | | 8% | 2 studies (2/-) | 45.7 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.54 [0.12, 2.33] | | < 1 | | 0% | 2 studies (2/-) | 79.6 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 1.00 [0.39, 2.55] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | low | not evaluable | high | non important | - |
| Dizziness AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.14 [0.40, 3.24] | | < 1 | | 0% | 2 studies (2/-) | 40.1 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 1.44 [0.54, 3.82] | | < 1 | | 0% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.82 [0.39, 1.69] | | < 1 | | 0% | 1 study (1/-) | 70.7 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.00 [0.09, 11.09] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 8.25 [1.02, 66.42] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 1.00 [0.02, 50.78] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Increased Lipase Level AE (grade 3-4) | 2.30 [0.70, 7.57] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 1.25 [0.79, 2.00] | | < 1 | | 0% | 2 studies (2/-) | 17.0 % | low | not evaluable | high | non important | - |
| Nausea AE (grade 3-4) | 0.40 [0.10, 1.61] | | < 1 | | 0% | 2 studies (2/-) | 90.1 % | low | not evaluable | high | non important | - |
| Neutropenia AE (grade 3-4) | 0.85 [0.49, 1.46] | | < 1 | | 75% | 2 studies (2/-) | 72.4 % | low | not evaluable | high | non important | - |
| Peripheral oedema AE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 0.98 [0.36, 2.67] | | < 1 | | 53% | 2 studies (2/-) | 51.2 % | low | not evaluable | high | non important | - |
| Pruritus AE (grade 3-4) | 1.00 [0.06, 16.06] | | < 1 | | 0% | 2 studies (2/-) | 49.9 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 0.76 [0.09, 6.52] | | < 1 | | 0% | 2 studies (2/-) | 59.9 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 3.12 [0.29, 33.87] | | < 1 | | 0% | 2 studies (2/-) | 17.6 % | low | not evaluable | high | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.88 [0.40, 1.91] | | < 1 | | 69% | 2 studies (2/-) | 62.9 % | low | not evaluable | high | non important | - |
| Vomiting AE (grade 3-4) | 0.38 [0.09, 1.67] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | low | not evaluable | high | non important | - |
